Get notified when AKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Nasdaq Minimum Bid Price Noncompliance (new) — Company received Nov 2025 notice for failing to maintain $1.00 bid price; must cure by May 25, 2026 or face delisting.
- Material Weakness (new) — Remediated complex transactions weakness but IT and purchase-to-pay weaknesses persist from prior year.
Akari narrows to ADC platform, writes off PHP-303, extends cash to April 2026 via dilutive raises
Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read
Key Changes
-
high
Company wrote off $5.2M PHP-303 asset, citing resource shift to ADC platform and failure to find partner. Removed PH5/PH6 payload programs and cut R&D headcount from 4 to 1, narrowing strategic focus to AKTX-101 and AKTX-102.
Business & MD&A verify on EDGAR → -
high
Received Nasdaq noncompliance notice Nov 2025 for failing $1.00 minimum bid price. Must cure by May 25, 2026 or face delisting. Announced 1:80,000 reverse ADS ratio change effective March 31, 2026 to boost trading price.
Risk Factors & MD&A verify on EDGAR → -
high
Raised ~$14M net proceeds via multiple 2025 financings (Oct/Dec equity offerings, Aug notes with 20% discount, $3.8M debt-to-equity exchange). Cash doubled to $5.2M but runway extends only to April 2026 at current $17M annual burn.
MD&A verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade AKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify